Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)

Abstract Background The overactivation of mineralocorticoid receptor (MR) plays a key pathological role in the progression of cardiovascular and renal diseases by promoting pro-inflammatory and pro-fibrotic signaling. Recently, it has been found that finerenone, a novel nonsteroidal selective MR ant...

Full description

Bibliographic Details
Main Authors: Atsushi Tanaka, Hirotaka Shibata, Takumi Imai, Hisako Yoshida, Motoaki Miyazono, Naohiko Takahashi, Daiju Fukuda, Yosuke Okada, Hiroki Teragawa, Satoru Suwa, Keisuke Kida, Masao Moroi, Isao Taguchi, Shigeru Toyoda, Michio Shimabukuro, Kengo Tanabe, Kenichi Tanaka, Masaomi Nangaku, Koichi Node, the FIVE-STAR trial investigators
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Cardiovascular Diabetology
Subjects:
Finerenone
Vascular stiffness
Biomarker
Type 2 diabetes
Chronic kidney disease
Online Access:https://doi.org/10.1186/s12933-023-01928-y

Internet

https://doi.org/10.1186/s12933-023-01928-y

Similar Items